ITM2B and Alzheimer disease: These differences can have several explanations, such as more aggressive development of AD pathology in AppNL-G-F mice, different doses of rh Bri2 BRICHOS R221E given, different durations between the last dose and biochemical analyses, as well as more time elapsed after AD-like pathology was established in AppNL-F mice until treatment was started compared with AppNL-G-F mice.